Attacking a moving target: Understanding resistance and managing progression in EGFR-positive lung cancer patients treated with tyrosine kinase inhibitors

Benjamin P. Levy, Parth Rao, Daniel J. Becker, Kevin Becker

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

In this article, we review the available literature addressing the competing treatment strategies in EGFR-Positive Lung Cancer and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.

Original languageEnglish
JournalOncology
Volume30
Issue number7
StatePublished - 15 Jul 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Attacking a moving target: Understanding resistance and managing progression in EGFR-positive lung cancer patients treated with tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this